AIMS: To develop a population pharmacokinetic model for pyrimethamine (PYR) and sulfadoxine (SDX) in children with congenital toxoplasmosis. METHODS: Children were treated with PYR (1.25 mg kg(-1)) and SDX (25 mg kg(-1)) (Fansidar) plus folinic acid (Lederfoline) 5 mg). Plasma concentrations, available from a therapeutic drug monitoring database, were determined by high-performance liquid chromatography. Population pharmacokinetic analysis was performed using a nonlinear mixed effects model. RESULTS: Eighty-nine children, aged 1 week to 14 years and weighing 2.9-59 kg, were available for evaluation. Both PYR and SDX concentration-time profiles were best described by a one-compartment open model. Volume of plasma distribution (V) and clearance (CL) were significantly related to body weight (BW) using an allometric function. Typical CL and V estimates (95% confidence interval), for a child weighing 11 kg were 5.50 (5.28, 5.73) l day(-1) and 36 (33, 39) l for PYR and 0.26 (0.25, 0.27) l day(-1) and 2.1 (1.9, 2.3) l for SDX. For BW between 3.5 and 60 kg, plasma half-lives were predicted to vary from 4.0 to 5.2 days for PYR, and from 5.0 to 7.5 days for SDX. CONCLUSION: This study indicated that body weight influences PYR and SDX pharmacokinetics in children. To optimize PYR/SDX combination treatment in congenital toxoplasmosis, short dosing intervals in very young low-wight children are probably appropriate.
AIMS: To develop a population pharmacokinetic model for pyrimethamine (PYR) and sulfadoxine (SDX) in children with congenital toxoplasmosis. METHODS:Children were treated with PYR (1.25 mg kg(-1)) and SDX (25 mg kg(-1)) (Fansidar) plus folinic acid (Lederfoline) 5 mg). Plasma concentrations, available from a therapeutic drug monitoring database, were determined by high-performance liquid chromatography. Population pharmacokinetic analysis was performed using a nonlinear mixed effects model. RESULTS: Eighty-nine children, aged 1 week to 14 years and weighing 2.9-59 kg, were available for evaluation. Both PYR and SDX concentration-time profiles were best described by a one-compartment open model. Volume of plasma distribution (V) and clearance (CL) were significantly related to body weight (BW) using an allometric function. Typical CL and V estimates (95% confidence interval), for a child weighing 11 kg were 5.50 (5.28, 5.73) l day(-1) and 36 (33, 39) l for PYR and 0.26 (0.25, 0.27) l day(-1) and 2.1 (1.9, 2.3) l for SDX. For BW between 3.5 and 60 kg, plasma half-lives were predicted to vary from 4.0 to 5.2 days for PYR, and from 5.0 to 7.5 days for SDX. CONCLUSION: This study indicated that body weight influences PYR and SDX pharmacokinetics in children. To optimize PYR/SDX combination treatment in congenital toxoplasmosis, short dosing intervals in very young low-wight children are probably appropriate.
Authors: S M Mansor; V Navaratnam; M Mohamad; S Hussein; A Kumar; A Jamaludin; W H Wernsdorfer Journal: Br J Clin Pharmacol Date: 1989-03 Impact factor: 4.335
Authors: F Daffos; F Forestier; M Capella-Pavlovsky; P Thulliez; C Aufrant; D Valenti; W L Cox Journal: N Engl J Med Date: 1988-02-04 Impact factor: 91.245
Authors: W Foulon; I Villena; B Stray-Pedersen; A Decoster; M Lappalainen; J M Pinon; P A Jenum; K Hedman; A Naessens Journal: Am J Obstet Gynecol Date: 1999-02 Impact factor: 8.661
Authors: P Hohlfeld; F Daffos; P Thulliez; C Aufrant; J Couvreur; J MacAleese; D Descombey; F Forestier Journal: J Pediatr Date: 1989-11 Impact factor: 4.406
Authors: Sam Salman; Susan Griffin; Kay Kose; Nolene Pitus; Josephine Winmai; Brioni Moore; Peter Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191
Authors: Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2009-07-20 Impact factor: 5.191
Authors: Basil T Thommen; Armin Passecker; Tamara Buser; Eva Hitz; Till S Voss; Nicolas M B Brancucci Journal: Front Cell Infect Microbiol Date: 2022-02-11 Impact factor: 5.293